Yusef Recalls SPF Lip Moisturizers with Excess Oxybenzone
Yusef Manufacturing is recalling 12,983 tubes of SPF 15 lip moisturizers because they contain up to 150% of the labeled amount of oxybenzone.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II. The hazard involves a superpotent drug concentration (150% of label claim) without reported injuries or illnesses, fitting the criteria for a moderate severity recall.
Plain-English summary
Yusef Manufacturing Laboratories, LLC is recalling 12,983 tubes of SPF 15 lip moisturizers. The affected products include Peppermint Lip Moisturizer, Flavored Lip Moisturizer, and Lip Moisturizer, all containing 4% oxybenzone and 7% octinoxate. The products were distributed nationwide within the United States and were sold under various labels, including Bimark Inc., NOCO TRAIL REPORT, Herbruck's, and several dental and medical practices.
The recall is due to the presence of a superpotent drug. The specific lot (Lot # 14381, Exp. Date 9/2023) contains up to 150% of the label claim for the active ingredient oxybenzone. This exceeds the intended concentration for the product.
Consumers should stop using the recalled lip moisturizers and return them to the place of purchase for a refund or contact Yusef Manufacturing Laboratories, LLC for further instructions.
The recalled product
- Product
- PEPPERMINT LIP MOISTURIZER (oxybenzone (4%) and Octinoxate (7%) SPF 15, 4.2 g tube, labeled as a) Bimark Inc., bimark.com; b) NOCO TRAIL REPORT, www.NoCoTrailReport.org; c) Herbruck's, d) St. Mark's Outpatient Surgery Center, 1250 East 3900 South Suite 100, Salt Lake City, UT…
- Manufacturer
- Yusef Manufacturing Laboratories, LLC
- Category
- Drug — Topical Sunscreen
- Affected units
- 12,983
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 14381
- Exp. Date 9/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Yusef Manufacturing Laboratories, LLC
See all →- ModerateRocky Mountain Sunscreen Lip Balm Recalled for Excess Octisalate
FDA (Drugs) · 2020-09-02
- SevereYusef Tropical Lip Moisturizer Recalled for Superpotent Meradimate Ingredient
FDA (Drugs) · 2020-08-12
Same hazard · superpotent drug
See all →- HighLevothyroxine Sodium Tablets Recalled Due to Potency Failures
FDA (Drugs) · 2024-12-18
- SevereLupin Recalls Cefprozil Oral Suspension Due to Superpotent Drug Concerns
FDA (Drugs) · 2021-04-21
- CriticalFerring Recalls STIMATE Nasal Spray Due to Superpotent Drug Risk
FDA (Drugs) · 2020-08-26
- CriticalFerring Recalls DDAVP Nasal Spray Due to Superpotent Drug Risk
FDA (Drugs) · 2020-08-26
- CriticalAcella Recalls Superpotent NP Thyroid 15 Tablets Nationwide
FDA (Drugs) · 2020-06-10
Similar recalls
- SevereYusef Tropical Lip Moisturizer Recalled for Superpotent Meradimate Ingredient
FDA (Drugs) · 2020-08-12
- ModerateRocky Mountain Sunscreen Lip Balm Recalled for Excess Octisalate
FDA (Drugs) · 2020-09-02
- ModerateJuice Beauty Lip Moisturizer recalled for failed dissolution specifications
FDA (Drugs) · 2022-08-03
- ModerateEcoLips Sport Lip Balm Recalled for Excessive Avobenzone Concentration
FDA (Drugs) · 2020-06-24
- ModerateShiseido Eye and Lip Collection Recalled for GMP Deviations
FDA (Drugs) · 2018-01-24
- ModerateMilbar Recalls Malin+Goetz SPF 30 Face Moisturizer Due to GMP Deviations
FDA (Drugs) · 2020-11-25